CA2372250A1 - Fimbrial proteins - Google Patents
Fimbrial proteins Download PDFInfo
- Publication number
- CA2372250A1 CA2372250A1 CA002372250A CA2372250A CA2372250A1 CA 2372250 A1 CA2372250 A1 CA 2372250A1 CA 002372250 A CA002372250 A CA 002372250A CA 2372250 A CA2372250 A CA 2372250A CA 2372250 A1 CA2372250 A1 CA 2372250A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- sequence listing
- subspecies
- vaccine
- salmonella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101710177917 Fimbrial protein Proteins 0.000 title description 2
- 241001138501 Salmonella enterica Species 0.000 claims abstract description 45
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 241001467018 Typhis Species 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 241000607142 Salmonella Species 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940023146 nucleic acid vaccine Drugs 0.000 claims description 4
- 229940126580 vector vaccine Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 6
- 238000002405 diagnostic procedure Methods 0.000 claims 3
- 241000894006 Bacteria Species 0.000 abstract description 10
- 238000001514 detection method Methods 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 28
- 239000000203 mixture Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 201000008297 typhoid fever Diseases 0.000 description 7
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 6
- 208000037386 Typhoid Diseases 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 101150038065 safA gene Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 101150094608 SAFB gene Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 101100148678 Neptuniibacter caesariensis safD gene Proteins 0.000 description 3
- 206010039438 Salmonella Infections Diseases 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- 101100406826 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) pagN gene Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010039447 salmonellosis Diseases 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010037833 Bacterial Adhesins Proteins 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 101710082149 Major fimbrial subunit Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101100045594 Mus musculus Tcf7 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001148138 Salmonella enterica subsp. enterica serovar Adelaide Species 0.000 description 1
- 241000592155 Salmonella enterica subsp. enterica serovar Agona Species 0.000 description 1
- 241000596091 Salmonella enterica subsp. enterica serovar Anatum Species 0.000 description 1
- 241000592148 Salmonella enterica subsp. enterica serovar Bareilly Species 0.000 description 1
- 241000581497 Salmonella enterica subsp. enterica serovar Blockley Species 0.000 description 1
- 241000592151 Salmonella enterica subsp. enterica serovar Bovismorbificans Species 0.000 description 1
- 241001355103 Salmonella enterica subsp. enterica serovar Braenderup Species 0.000 description 1
- 241001355140 Salmonella enterica subsp. enterica serovar Brandenburg Species 0.000 description 1
- 241000940095 Salmonella enterica subsp. enterica serovar Bredeney Species 0.000 description 1
- 241001135268 Salmonella enterica subsp. enterica serovar Derby Species 0.000 description 1
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241001355131 Salmonella enterica subsp. enterica serovar Hadar Species 0.000 description 1
- 241000607726 Salmonella enterica subsp. enterica serovar Heidelberg Species 0.000 description 1
- 241000607128 Salmonella enterica subsp. enterica serovar Infantis Species 0.000 description 1
- 241000273970 Salmonella enterica subsp. enterica serovar Java Species 0.000 description 1
- 241000273971 Salmonella enterica subsp. enterica serovar Kottbus Species 0.000 description 1
- 241001355102 Salmonella enterica subsp. enterica serovar London Species 0.000 description 1
- 241001437645 Salmonella enterica subsp. enterica serovar Mbandaka Species 0.000 description 1
- 241000210647 Salmonella enterica subsp. enterica serovar Montevideo Species 0.000 description 1
- 241001635184 Salmonella enterica subsp. enterica serovar Muenster Species 0.000 description 1
- 241000235830 Salmonella enterica subsp. enterica serovar Ohio Species 0.000 description 1
- 241001135250 Salmonella enterica subsp. enterica serovar Oranienburg Species 0.000 description 1
- 241001148137 Salmonella enterica subsp. enterica serovar Panama Species 0.000 description 1
- 241000607121 Salmonella enterica subsp. enterica serovar Potsdam Species 0.000 description 1
- 241000947639 Salmonella enterica subsp. enterica serovar Rissen Species 0.000 description 1
- 241000293246 Salmonella enterica subsp. enterica serovar Saintpaul Species 0.000 description 1
- 241001437646 Salmonella enterica subsp. enterica serovar Stanley Species 0.000 description 1
- 241001282571 Salmonella enterica subsp. enterica serovar Tennessee Species 0.000 description 1
- 241000607686 Salmonella enterica subsp. enterica serovar Thompson Species 0.000 description 1
- 241000230602 Salmonella enterica subsp. enterica serovar Virchow Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 101150016526 fadE gene Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 101150028179 yafV gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901961A SE9901961D0 (sv) | 1999-05-28 | 1999-05-28 | Fimbrial proteins |
| SE9901961-4 | 1999-05-28 | ||
| PCT/SE2000/001079 WO2000073336A1 (en) | 1999-05-28 | 2000-05-26 | Fimbrial proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2372250A1 true CA2372250A1 (en) | 2000-12-07 |
Family
ID=20415789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002372250A Abandoned CA2372250A1 (en) | 1999-05-28 | 2000-05-26 | Fimbrial proteins |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1180118A1 (sv) |
| JP (1) | JP2003502291A (sv) |
| AU (1) | AU773484B2 (sv) |
| CA (1) | CA2372250A1 (sv) |
| NZ (1) | NZ515912A (sv) |
| SE (1) | SE9901961D0 (sv) |
| WO (1) | WO2000073336A1 (sv) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60216099D1 (de) * | 2001-05-17 | 2006-12-28 | Creatogen Ag | Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben |
| AU2009254932A1 (en) | 2008-06-03 | 2009-12-10 | Health Protection Agency | Salmonella detection assay |
-
1999
- 1999-05-28 SE SE9901961A patent/SE9901961D0/sv unknown
-
2000
- 2000-05-26 CA CA002372250A patent/CA2372250A1/en not_active Abandoned
- 2000-05-26 JP JP2001500660A patent/JP2003502291A/ja active Pending
- 2000-05-26 AU AU52628/00A patent/AU773484B2/en not_active Ceased
- 2000-05-26 WO PCT/SE2000/001079 patent/WO2000073336A1/en not_active Application Discontinuation
- 2000-05-26 EP EP00937458A patent/EP1180118A1/en not_active Withdrawn
- 2000-05-26 NZ NZ515912A patent/NZ515912A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE9901961D0 (sv) | 1999-05-28 |
| WO2000073336A1 (en) | 2000-12-07 |
| AU773484B2 (en) | 2004-05-27 |
| AU5262800A (en) | 2000-12-18 |
| JP2003502291A (ja) | 2003-01-21 |
| NZ515912A (en) | 2004-02-27 |
| EP1180118A1 (en) | 2002-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corbel | Brucellosis: an overview. | |
| Konjufca et al. | A recombinant attenuated Salmonella enterica serovar Typhimurium vaccine encoding Eimeria acervulina antigen offers protection against E. acervulina challenge | |
| Wen et al. | Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge | |
| US20120258129A1 (en) | Mycobacterium tuberculosis fusion protein and uses thereof | |
| US20080241151A1 (en) | Virulence genes, proteins, and their use | |
| Lalsiamthara et al. | Intermediate rough Brucella abortus S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice | |
| AU2013311670B2 (en) | A novel live attenuated Shigella vaccine | |
| Dehio et al. | Bartonella as emerging pathogens: The 1st International Conference on Bartonella as Emerging Pathogens, organized by C. Dehio and A. Sander, was held at the Max-Planck-Institute, Tübingen, Germany, 5–7 March 1999. | |
| CZ20014030A3 (cs) | Oslabené mikroorganismy pro léčbu infekce | |
| Venkatesan et al. | Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain | |
| Venkatesan et al. | Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine | |
| Konjufca et al. | Immunogenicity of recombinant attenuated Salmonella enterica serovar Typhimurium vaccine strains carrying a gene that encodes Eimeria tenella antigen SO7 | |
| Tacket et al. | Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies | |
| Thornton et al. | Polynucleotide sequence relationships among flagellin genes of Campylobacter jejuni and Campylobacter coli | |
| Asper et al. | Cross reactivity of enterohemorrhagic Escherichia coli O157: H7-specific sera with non-O157 serotypes | |
| CA2372250A1 (en) | Fimbrial proteins | |
| Tadepalli et al. | Intraperitoneal administration of a novel chimeric immunogen (rOP) elicits IFN-γ and IL-12p70 protective immune response in BALB/c mice against virulent Brucella | |
| CN101629159B (zh) | 流产布鲁氏菌重组菌及其应用 | |
| EP1019522A1 (en) | Compositions and methods for administering pneumococcal dna | |
| Faundez et al. | Chromosomal DNA, iron-transport systems, outer membrane proteins, and enterotoxin (heat labile) production in Salmonella typhi strains | |
| WO2009032978A2 (en) | Compositions and methods for diagnosing and treating urinary tract infections | |
| US11471520B2 (en) | Enhanced Shigella-enterotoxigenic E. coli multi-valent vaccine | |
| Delcayre et al. | A genome-based functional screening approach to vaccine development that combines in vitro assays and DNA immunization | |
| Oloomi et al. | A recombinant hybrid peptide composed of AAF adhesin of enteroaggregative Escherichia coli and Shiga toxin B subunit elicits protective immune response in mice | |
| Pang et al. | Report from an international symposium on typhoid fever. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |